Dose interval injection extension and costs of lanreotide Autogel 120 mg used in routine acromegaly care in Poland: 2 years data from Lanro study

Ewa Orlewska; Beata Kos-Kudla; Jerzy Sowinski; Krzysztof Sworczak; Wojciech Zgliczynski

doi:10.1530/endoabs.37.EP666

EP666

Prev Next

Section Contents Cite

Endocrine Abstracts (2015) 37 EP666 | DOI: 10.1530/endoabs.37.EP666

ECE2015 Eposter Presentations Pituitary: basic and neuroendocrinology (62 abstracts)

Dose interval injection extension and costs of lanreotide Autogel 120 mg used in routine acromegaly care in Poland: 2 years data from Lanro study

Ewa Orlewska ¹ , Beata Kos-Kudla ² , Jerzy Sowinski ³ , Krzysztof Sworczak ⁴ & Wojciech Zgliczynski ⁵

Err

Author affiliations View ePoster Download ePoster

¹Faculty of Health Sciences, The Jan Kochanowski University, Kielce, Poland; ²Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice, Poland; ³Chair and Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland; ⁴Endocrinology and Internal Diseases Department, Medical University, Gdansk, Poland; ⁵Centre of Postgraduate Medical Education, Warsaw, Poland.

Objective: To determine the percentage of patients with acromegaly who received lanreotide Autogel 120 mg (ATG120) in extended duration interval and to evaluate the mean costs of ATG120 administered as part of routine care in Poland.

Methods: National, multicentre, non-interventional, observational prospective study with 2-years’ time horizon. The study population consisted of adult acromegaly patients who received at least three injections of ATG120 before inclusion. The endpoints were: percentage of patients treated with ATG120 at an extended duration interval (>4 weeks) and mean cost of ATG120. Costs were calculated in PLN from the public health-care payer and patient perspective for the year 2014 (one PLN=0.25 EURO).

Results: 151 patients suffering from acromegaly for at least 1 year were screened and 143 enrolled in 35 centres. Of those, 11 patients were excluded from the analysis because of missing of follow-up visits or because they did not complete the treatment period. 70% of them were women, 81% had macroadenoma, and 75% underwent surgical treatment in the past. During 2 years, changes in the treatment pattern – decrease or increase of injection interval or change of treatment, were reported in 41 (31%) patients. In other patients treatment has not been changed. 63 patients (48%) received ATG120 at an extended duration interval. The mean number of days between injections was 35.1 (S.D. 8.2). ATG120 was predominantly administered in out-patient setting (84%) and by health-care professional (97%). The mean cost of ATG120 per patient per month was 4062.5 PLN and 3.6 PLN from the public payer and patient perspective respectively. Meanwhile the retail price of ATG120 per pack is 4770.5 PLN.

Conclusion: The results demonstrated that extended duration interval of ATG120 is used in almost half of acromegaly patients, indicating the reduction of financial burden for the health care system.

Disclosure: This study was founded by Ipsen Poland sp. z o.o.